These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

466 related items for PubMed ID: 27184482

  • 21. Clinical and pathologic predictors of clinical outcome of malignant pleural mesothelioma.
    Berardi R, Fiordoliva I, De Lisa M, Ballatore Z, Caramanti M, Morgese F, Savini A, Rinaldi S, Torniai M, Tiberi M, Ferrini C, Onofri A, Cascinu S.
    Tumori; 2016; 102(2):190-5. PubMed ID: 26893272
    [Abstract] [Full Text] [Related]

  • 22. Clinical, histologic, and genetic features of mesothelioma in a 7-year-old child.
    Sugalski A, Davis M, Prasannan L, Saldivar V, Hung JY, Tomlinson GE.
    Pediatr Blood Cancer; 2013 Jan; 60(1):146-8. PubMed ID: 22961710
    [Abstract] [Full Text] [Related]

  • 23. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
    Forest F, Patoir A, Dal Col P, Sulaiman A, Camy F, Laville D, Bayle-Bleuez S, Fournel P, Habougit C.
    Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
    [Abstract] [Full Text] [Related]

  • 24. Genomic Deletion of BAP1 and CDKN2A Are Useful Markers for Quality Control of Malignant Pleural Mesothelioma (MPM) Primary Cultures.
    Sarun KH, Lee K, Williams M, Wright CM, Clarke CJ, Cheng NC, Takahashi K, Cheng YY.
    Int J Mol Sci; 2018 Oct 07; 19(10):. PubMed ID: 30301262
    [Abstract] [Full Text] [Related]

  • 25. The clinicopathological significance of TOP2A expression in malignant peritoneal mesothelioma.
    Du X, Li X, Zhang B, Hao Z, Gao Y, Jiang X, Yang Z, Chen Y.
    Ann Diagn Pathol; 2023 Aug 07; 65():152155. PubMed ID: 37172528
    [Abstract] [Full Text] [Related]

  • 26. Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy.
    Li YC, Khashab T, Terhune J, Eckert RL, Hanna N, Burke A, Richard Alexander H.
    Ann Surg Oncol; 2017 Aug 07; 24(8):2259-2265. PubMed ID: 28324285
    [Abstract] [Full Text] [Related]

  • 27. Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival.
    Verma V, Sleightholm RL, Rusthoven CG, Koshy M, Sher DJ, Grover S, Simone CB.
    Ann Surg Oncol; 2018 Jul 07; 25(7):2018-2026. PubMed ID: 29721724
    [Abstract] [Full Text] [Related]

  • 28. Repeat cytoreductive surgery and heated intraperitoneal chemotherapy may offer survival benefit for intraperitoneal mesothelioma: a single institution experience.
    Wong J, Koch AL, Deneve JL, Fulp W, Tanvetyanon T, Dessureault S.
    Ann Surg Oncol; 2014 May 07; 21(5):1480-6. PubMed ID: 24158467
    [Abstract] [Full Text] [Related]

  • 29. Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia.
    Alì G, Borrelli N, Riccardo G, Proietti A, Pelliccioni S, Niccoli C, Boldrini L, Lucchi M, Mussi A, Fontanini G.
    J Thorac Oncol; 2013 Nov 07; 8(11):1389-95. PubMed ID: 24084442
    [Abstract] [Full Text] [Related]

  • 30. A cluster of familial malignant mesothelioma with del(9p) as the sole chromosomal anomaly.
    Musti M, Cavone D, Aalto Y, Scattone A, Serio G, Knuutila S.
    Cancer Genet Cytogenet; 2002 Oct 01; 138(1):73-6. PubMed ID: 12419589
    [Abstract] [Full Text] [Related]

  • 31. Prognostic significance of Ki67 expression in malignant peritoneal mesothelioma.
    Pillai K, Pourgholami MH, Chua TC, Morris DL.
    Am J Clin Oncol; 2015 Aug 01; 38(4):388-94. PubMed ID: 26214083
    [Abstract] [Full Text] [Related]

  • 32. Association Between Clinicopathological Factors and Genomic Abnormalities Detected by FISH Analysis in Epithelioid Diffuse Malignant Pleural Mesothelioma.
    Takeda M, Kasai T, Hatakeyama K, Nakai T, Itami H, Uchiyama T, IIzuka N, Maruyama H, Ohbayashi C.
    Int J Surg Pathol; 2017 Dec 01; 25(8):668-673. PubMed ID: 28673192
    [Abstract] [Full Text] [Related]

  • 33. Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers.
    Bononi I, Comar M, Puozzo A, Stendardo M, Boschetto P, Orecchia S, Libener R, Guaschino R, Pietrobon S, Ferracin M, Negrini M, Martini F, Bovenzi M, Tognon M.
    Oncotarget; 2016 Dec 13; 7(50):82700-82711. PubMed ID: 27716620
    [Abstract] [Full Text] [Related]

  • 34. [Malignant mesothelioma in Basse-Normandie, a French population study. Descriptive analysis, prognostic factors and survival].
    Desoubeaux N, Bouvier V, Gervais R, Galateau-Salle F, Thibon P, Leplumey T, Herbert C, Lecherbonnier Y, Daviet JP, Letourneux M.
    Rev Epidemiol Sante Publique; 2001 Dec 13; 49(6):523-9. PubMed ID: 11845101
    [Abstract] [Full Text] [Related]

  • 35. Incidence and survival trends for malignant pleural and peritoneal mesothelioma, Australia, 1982-2009.
    Soeberg MJ, Leigh J, Driscoll T, Armstrong B, Young JM, van Zandwijk N.
    Occup Environ Med; 2016 Mar 13; 73(3):187-94. PubMed ID: 26800709
    [Abstract] [Full Text] [Related]

  • 36. Genome-based Mutational Analysis by Next Generation Sequencing in Patients with Malignant Pleural and Peritoneal Mesothelioma.
    Ugurluer G, Chang K, Gamez ME, Arnett AL, Jayakrishnan R, Miller RC, Sio TT.
    Anticancer Res; 2016 May 13; 36(5):2331-8. PubMed ID: 27127140
    [Abstract] [Full Text] [Related]

  • 37. Differential Susceptibility of Human Pleural and Peritoneal Mesothelial Cells to Asbestos Exposure.
    Dragon J, Thompson J, MacPherson M, Shukla A.
    J Cell Biochem; 2015 Aug 13; 116(8):1540-52. PubMed ID: 25757056
    [Abstract] [Full Text] [Related]

  • 38. Malignant Peritoneal Mesothelioma: Patterns of Care and Survival in the Netherlands: A Population-Based Study.
    de Boer NL, van Kooten JP, Damhuis RAM, Aerts JGJV, Verhoef C, Madsen EVE.
    Ann Surg Oncol; 2019 Dec 13; 26(13):4222-4228. PubMed ID: 31620941
    [Abstract] [Full Text] [Related]

  • 39. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
    Cedrés S, Ponce-Aix S, Zugazagoitia J, Sansano I, Enguita A, Navarro-Mendivil A, Martinez-Marti A, Martinez P, Felip E.
    PLoS One; 2015 Dec 13; 10(3):e0121071. PubMed ID: 25774992
    [Abstract] [Full Text] [Related]

  • 40. MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data.
    Pasello G, Urso L, Mencoboni M, Grosso F, Ceresoli GL, Lunardi F, Vuljan SE, Bertorelle R, Sacchetto V, Ciminale V, Rea F, Favaretto A, Conte P, Calabrese F.
    Oncotarget; 2015 Dec 08; 6(39):42053-66. PubMed ID: 26544728
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.